300 related articles for article (PubMed ID: 21918819)
21. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
Gupta SK
AIDS Patient Care STDS; 2008 Feb; 22(2):99-103. PubMed ID: 18260800
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.
Riordan A; Judd A; Boyd K; Cliff D; Doerholt K; Lyall H; Menson E; Butler K; Gibb D;
Pediatr Infect Dis J; 2009 Mar; 28(3):204-9. PubMed ID: 19209091
[TBL] [Abstract][Full Text] [Related]
23. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC
AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV.
Lucey JM; Hsu P; Ziegler JB
BMJ Case Rep; 2013 Jul; 2013():. PubMed ID: 23843401
[TBL] [Abstract][Full Text] [Related]
25. Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature.
Haverkort ME; van der Spek BW; Lips P; Slieker WA; ter Heine R; Huitema AD; Bronsveld W
Scand J Infect Dis; 2011 Oct; 43(10):821-6. PubMed ID: 21563880
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
27. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
González-García J; Cohen D; Johnson M; Sloan L; Fredrick L; Naylor C; da Silva B; Bernstein B;
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):841-5. PubMed ID: 20672994
[TBL] [Abstract][Full Text] [Related]
28. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection.
Perry CM
Drugs; 2009; 69(7):843-57. PubMed ID: 19441871
[TBL] [Abstract][Full Text] [Related]
29. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Breton G; Alexandre M; Duval X; Prie D; Peytavin G; Leport C; Vildei JL
Scand J Infect Dis; 2004; 36(6-7):527-8. PubMed ID: 15307594
[TBL] [Abstract][Full Text] [Related]
30. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.
Palacios R; Rivero A; Santos I; Ríos MJ; Castaño M; del Arco A; Santos González J;
HIV Clin Trials; 2010; 11(2):118-20. PubMed ID: 20542848
[No Abstract] [Full Text] [Related]
31. Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
McGee KC; Shahmanesh M; Boothby M; Nightingale P; Gathercole LL; Tripathi G; Harte AL; Shojaee-Moradie F; Umpleby AM; Das S; Al-Daghri NM; McTernan PG; Tomlinson JW
Antivir Ther; 2012; 17(3):495-507. PubMed ID: 22300946
[TBL] [Abstract][Full Text] [Related]
32. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Pulido F; Fiorante S
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
[TBL] [Abstract][Full Text] [Related]
33. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection.
Gracey DM; Snelling P; McKenzie P; Strasser SI
Antivir Ther; 2013; 18(7):945-8. PubMed ID: 23839869
[TBL] [Abstract][Full Text] [Related]
34. [Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Ondounda M; Tanon A; Ehui E; Ouattara I; Kassi A; Aba YT; Aoussi EF; Kakou AR; Eholié SP; Bissagnene E; Kadio A
Med Mal Infect; 2011 Feb; 41(2):105-7. PubMed ID: 20832214
[No Abstract] [Full Text] [Related]
35. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
[No Abstract] [Full Text] [Related]
36. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Boothby M; McGee KC; Tomlinson JW; Gathercole LL; McTernan PG; Shojaee-Moradie F; Umpleby AM; Nightingale P; Shahmanesh M
Antivir Ther; 2009; 14(8):1089-100. PubMed ID: 20032539
[TBL] [Abstract][Full Text] [Related]
37. The impact of gender and anchor drugs on TDF renal toxicity.
Quiros-Roldan E; Amadasi S; Paraninfo G; Izzo I; Allegri R; Motta D; Gatti F; Cristini G; Carosi G; Mendeni M; Torti C
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):e11-2. PubMed ID: 20859083
[No Abstract] [Full Text] [Related]
38. [HIV infected women with intense bone and muscular pain and general weakness].
Pérez-Rivera AÁ; Sáez P; León E; Lozano de León-Naranjo F
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):308-10. PubMed ID: 21334782
[No Abstract] [Full Text] [Related]
39. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Smith DE; Chan DJ; Maruszak H; Jeganathan S
Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757
[TBL] [Abstract][Full Text] [Related]
40. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
Day SL; Leake Date HA; Bannister A; Hankins M; Fisher M
J Acquir Immune Defic Syndr; 2005 Mar; 38(3):301-4. PubMed ID: 15735448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
